Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients with Bipolar I Disorder

AI Summary

Initiating OLZ/SAM was associated with significant reductions in inpatient admissions and emergency department visits versus baseline (reductions 16.4% to 42.1%; P < 0.001).
Mean inpatient days per patient decreased significantly by 3.9 to 4.6 days over 12 months (P < 0.001).
Greater treatment persistence yielded larger reductions in acute care HCRU; 29.9% of patients remained on OLZ/SAM for the full 12 months.

TL;DR (AI Generated)

INTRODUCTION: This real-world data analysis examined healthcare resource utilization (HCRU) among patients with bipolar I disorder (BD-I) in the 12 months before and after initiating a combination of olanzapine and samidorphan (OLZ/SAM).

Proportions of patients with ≥ 1 OP visit were similar before and after starting OLZ/SAM, indicating that patients continued receiving OP care.

Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the entire 12-month follow-up period; these reductions were observed to be larger than those observed in the full cohort.

Basic summary

Adv Ther. 2026 Nov 13. doi: 10.1007/s12325-026-03807-w. Online ahead of print.

ABSTRACT

METHODS: This retrospective analysis used administrative claims data (October 18, 2020-December 31, 2023) from the Komodo Healthcare Map. Eligibility criteria included age ≥ 18 years and continuous enrollment in medical and pharmacy benefits ≥ 12 months before (baseline) and after (follow-up) initiating OLZ/SAM. Comparisons between baseline and follow-up included inpatient (IP) admissions, emergency department (ED) and outpatient (OP) visits, and average number of IP days/patient. A subgroup analysis of patients receiving OLZ/SAM for the full 12-month follow-up period was conducted.

RESULTS: Overall, 1004 patients with BD-I who initiated OLZ/SAM were included. Mean (SD) age was 39.0 (12.5) years; 691 (68.8%) were female. Mean (SD) persistence was 173.7 (139.9) days. Overall, 300 (29.9%) patients received continuous OLZ/SAM treatment for the full 12-month follow-up period. Proportions of patients with ≥ 1 all-cause, mental health-related, or BD-I-related IP admission or ED visit between baseline and follow-up were significantly reduced (range – 16.4% to – 42.1%; all P < 0.001), as were mean numbers of IP days/patient (range – 3.9 to – 4.6 days; all P < 0.001). Proportions of patients with ≥ 1 OP visit were similar before and after starting OLZ/SAM, indicating that patients continued receiving OP care. Significant reductions in IP admissions and ED visits were also observed in patients receiving OLZ/SAM treatment for the entire 12-month follow-up period; these reductions were observed to be larger than those observed in the full cohort.

CONCLUSION: Among patients with BD-I, initiating OLZ/SAM was associated with significant and clinically meaningful reductions in acute care HCRU compared with baseline. Larger reductions in acute HCRU were observed among patients with greater treatment persistence. Video abstract available for this article. Supplementary file1 (mp4 225 KB).

PMID:43024144 | DOI:10.1007/s12325-026-03807-w

Document this CPD